Genetic polymorphism CYP2C19 and its relation to pharmacokinetics and acid-suppression effect of proton pump inhibitors

被引：0
作者：
Niu, CY
Luo, JY
机构：
来源：
GASTROENTEROLOGY | 2004年 / 126卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A536 / A536
页数：1
相关论文
共 50 条
  • [31] Effect of CYP2C19*2 and*17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians
    Hunfeld, Nicole G.
    Mathot, Ron A.
    Touw, Daan J.
    van Schaik, Ron H.
    Mulder, Paul G.
    Franck, Paul F.
    Kuipers, Ernst J.
    Geus, William P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 752 - 760
  • [32] Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review
    Ibrahim, Asmaa
    Yusuff, Kazeem
    Awaisu, Ahmed
    Elewa, Hazem
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [33] Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem - Reply
    Klotz, U.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (03) : 189 - 190
  • [34] A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism
    Miyoshi, M
    Mizuno, M
    Ishiki, K
    Nagahara, Y
    Maga, T
    Torigoe, T
    Nasu, J
    Okada, H
    Yokota, K
    Oguma, K
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (07) : 723 - 728
  • [35] Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite
    Damle, Bharat D.
    Uderman, Howard
    Biswas, Pinaki
    Crownover, Penelope
    Lin, Chang
    Glue, Paul
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 682 - 689
  • [36] In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease
    Ohnishi, A
    Murakami, S
    Akizuki, S
    Mochizuki, J
    Echizen, H
    Takagi, I
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11) : 1221 - 1229
  • [37] Influence of clarithromycin on the pharmacokinetics/pharmacodynamics of lansoprazole in relation to CYP2C19 polymorphism.
    Sohn, DR
    Kim, HK
    Kwon, JT
    Ishizaki, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 160 - 160
  • [38] The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
    Sychev, D. A.
    Denisenko, N. P.
    Sizova, Z. M.
    Grachev, A. V.
    Velikolug, K. A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 111 - 114
  • [39] THE FREQUENCY OF CYP2C19 GENETIC POLYMORPHISMS IN RUSSIAN PATIENTS WITH PEPTIC ULCER TREATED WITH PROTON PUMP INHIBITORS
    Denisenko, N. P.
    Sychev, D. A.
    Sizova, Zh. M.
    Grachev, A. V.
    Velikolug, K. A.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E25 - E25
  • [40] Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)
    Ulrich Klotz
    European Journal of Clinical Pharmacology, 2009, 65
12345